Market Overview

Novo Nordisk Posts 35% Rise In Q3 Profit, Lifts 2012 Forecast

Related NVO
Ablynx Announces Nanobody Drug Discovery Collaboration, Licence Agreement With Novo Nordisk
Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications and Amends GLP-1 Agreement
XOMA licenses XMetA program to Novo Nordisk for diabetes for up to $295M (Seeking Alpha)

Novo Nordisk A/S (NYSE: NVO) reported a 35% rise in its third-quarter net profit and lifted its full-year earnings forecast.

Novo Nordisk's quarterly net profit surged to DKK5.67 billion, from DKK4.20 billion, in the year-ago period. However, analysts were expecting a profit of DKK5.27 billion.

Novo Nordisk shares closed at $161.29 yesterday.

Posted-In: profitEarnings News Guidance


Related Articles (NVO)

View Comments and Join the Discussion!

Get Benzinga's Newsletters